An observational study in Behcet's Disease, Albumin and Lactate Dehydrogenase, sponsored by Ataturk University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-26.
Sponsored by Ataturk University · Observational
ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls.
Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio.
136 studies on the registry are indexed under Behcet Syndrome; 43 are open to participants now.
This study's enrollment of 1 is below the median of 90 across 63 observational studies indexed under Behcet Syndrome.
Browse Behcet Syndrome studies →Ataturk University is the lead sponsor of 442 studies on the registry; 121 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A total of 349 subjects, including 160 patients with Behçet's disease and 189 healthy controls
Patients with Behçet's disease aged 18-69
Exclusion Criteria:
Diagnostic Test: LDH/albumin ratio
Diagnostic Test: LDH/albumin ratio
LDH/Albumin ratios of patient and control groups were recorded.
LDH/albumin ratio
Time frame: February 2020 and April 2023
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ataturk University